Literature DB >> 11179679

Characterization of mouse epithelial protein lost in neoplasm (EPLIN) and comparison of mammalian and zebrafish EPLIN.

R S Maul1, C Sachi Gerbin, D D Chang.   

Abstract

EPLIN is a cytoskeleton-associated protein that was initially identified as the product of a gene that is transcriptionally down-regulated in cancer cells. In human, there are two known isoforms, EPLIN-alpha and -beta, generated by alternative promoter usage from a single gene. With the exception of a single LIM (lin-11, isl-1, and mec-3) domain, the sequence of EPLIN is unique and does not provide any clues to its function. To identify conserved regions of EPLIN that may be important for its function, we have characterized mouse (m) and zebrafish (zf) EPLIN. As in human, two isoforms, the 593 aa mEPLIN-alpha (77% identity; 83% similarity) and 753 aa mEPLIN-beta (75% identity; 83% similarity), were present in mouse. mEPLIN-alpha is highly expressed in embryonic tissue and adult lung and spleen, whereas mEPLIN-beta is preferentially expressed in kidney, testis, lung and liver. The analysis of mEPLIN gene revealed that the overall organization of the exons in mouse and human are conserved. In zebrafish, there was only one form, the 629 aa zfEPLIN, corresponding to the mammalian EPLIN-beta. Like its mammalian counterparts, ectopically expressed zfEPLIN is co-localized to the actin cytoskeleton. While the overall homology between mammalian and zebrafish EPLIN was not striking (37% identity; 50% similarity), there were seven highly conserved regions, which should be useful in structure-function studies of this novel protein.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11179679     DOI: 10.1016/s0378-1119(00)00540-0

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  8 in total

1.  Inhibition of anchorage-independent growth of transformed NIH3T3 cells by epithelial protein lost in neoplasm (EPLIN) requires localization of EPLIN to actin cytoskeleton.

Authors:  Yuhong Song; Raymond S Maul; C Sachi Gerbin; David D Chang
Journal:  Mol Biol Cell       Date:  2002-04       Impact factor: 4.138

Review 2.  The state of the art of the zebrafish model for toxicology and toxicologic pathology research--advantages and current limitations.

Authors:  Jan M Spitsbergen; Michael L Kent
Journal:  Toxicol Pathol       Date:  2003 Jan-Feb       Impact factor: 1.902

3.  EPLINβ Is Involved in the Assembly of Cadherin-catenin Complexes in Osteoblasts and Affects Bone Formation.

Authors:  Shihoko Miyazaki; Taro Funamoto; Tomohisa Sekimoto; Syuji Kurogi; Tomomi Ohta; Takuya Nagai; Takuya Tajima; Mai Imasaka; Kumiko Yoshinobu; Kimi Araki; Masatake Araki; Narantsog Choijookhuu; Yoshitaka Hishikawa; Etsuo Chosa
Journal:  Acta Histochem Cytochem       Date:  2022-06-25       Impact factor: 1.857

4.  Analysis of her1 and her7 mutants reveals a spatio temporal separation of the somite clock module.

Authors:  Suma Choorapoikayil; Bernd Willems; Peter Ströhle; Martin Gajewski
Journal:  PLoS One       Date:  2012-06-18       Impact factor: 3.240

Review 5.  EPLIN: a fundamental actin regulator in cancer metastasis?

Authors:  Ross J Collins; Wen G Jiang; Rachel Hargest; Malcolm D Mason; Andrew J Sanders
Journal:  Cancer Metastasis Rev       Date:  2015-12       Impact factor: 9.264

6.  LUZP1 and the tumor suppressor EPLIN modulate actin stability to restrict primary cilia formation.

Authors:  João Gonçalves; Amit Sharma; Étienne Coyaud; Estelle M N Laurent; Brian Raught; Laurence Pelletier
Journal:  J Cell Biol       Date:  2020-07-06       Impact factor: 10.539

7.  EPLIN Expression in Gastric Cancer and Impact on Prognosis and Chemoresistance.

Authors:  Wenjing Gong; Jianyuan Zeng; Jiafu Ji; Yongning Jia; Shuqin Jia; Andrew J Sanders; Wen G Jiang
Journal:  Biomolecules       Date:  2021-04-08

8.  Eplin-alpha expression in human breast cancer, the impact on cellular migration and clinical outcome.

Authors:  Wen G Jiang; Tracey A Martin; Jonathan M Lewis-Russell; Anthony Douglas-Jones; Lin Ye; Robert E Mansel
Journal:  Mol Cancer       Date:  2008-09-16       Impact factor: 27.401

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.